The efficacy of daclizumab for intestinal transplantation: Preliminary report

We previously identified rejection as the most significant risk factor for intestinal allograft survival.1 The reported efficacy of daclizumab (Zenapax. Hoffman-LaRoche) prophylaxis with solid organ transplantation2 triggered its use at our center as induction therapy for intestinal transplantation.